Nan Geng¹, Wenxia Hu¹, Zhikun Liu², Jingwei Su², Wenyu Sun³, Shaonan Xie⁴, Cuimin Ding^1,*

Oncologie, Vol.22, No.4, pp. 245-254, 2020, DOI:10.32604/oncologie.2020.014125

Abstract Objective: This study was set out to inquire into the expression and clinical significance of lncRNA activated by transforming growth factor β (LncRNA-ATB) and in cancer tissues of patients with non-small cell lung cancer (NSCLC). Methods: LncRNA-ATB in cancer tissues and adjacent tissues of 89 NSCLC patients was detected by quantitative real-time polymerase chain reaction (qRT-PCR), and its clinical diagnostic value in NSCLC was determined by receiver operating characteristic (ROC) curves. Based on the median expression of LncRNAATB in NSCLC tissues, 89 patients were allocated into high- and low-expression groups. The 3-year survival rate was… More >

Mehmet Sitki Copur^*†, Julie Marie Wurdeman^†, Debra Nelson^*, Ryan Ramaekers^*, Dron Gauchan^*, David Crockett^*

Oncology Research, Vol.26, No.3, pp. 515-518, 2018, DOI:10.3727/096504017X15128550060375

Abstract Solid tumors involving glandular organs express mucin glycoprotein that is eventually shed into the circulation. As a result, these proteins can easily be measured in the serum and be used as potential tumor markers. The most commonly used tumor markers for breast cancer are CA27-29 and CA15-3, which both measure the glycoprotein product of the mucin-1 (MUC1) gene. CA27-29 has been approved by the US Food and Drug Administration for monitoring disease activity in breast cancer patients. Most oncology clinical practice guidelines do not recommend the use of tumor markers for routine surveillance of early… More >